(Q28728031)

English

Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor

scientific article (publication date: 2012)

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor (English)

0 references

object named as

Lone Skov

7

0 references

author name string

Nannie Bangsgaard

1

0 references

Mischa Houtkamp

2

0 references

Danita H Schuurhuis

3

0 references

Paul W H I Parren

4

0 references

Ole Baadsgaard

5

0 references

Hans W M Niessen

6

0 references

language of work or name

0 references

publication date

2012

0 references

0 references

7

0 references

6

0 references

e39706

0 references

copyright license

Creative Commons Attribution 4.0 International

25 June 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

17 March 2017

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

17 March 2017

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

7 April 2017

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Epidermal growth factor receptor inhibitors in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

The epidermal growth factor receptor system in skin repair and inflammation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Mechanisms of cutaneous toxicities to EGFR inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Cetuximab-induced acne

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Cutaneous side-effects of kinase inhibitors and blocking antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

The EGF receptor - an essential regulator of multiple epidermal functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

EGF-R dependent regulation of keratinocyte survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Comparison of Epidermal Growth Factor Binding and Receptor Distribution in Normal Human Epidermis and Epidermal Appendages

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human Skin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

3 June 2018

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039706

21 January 2018

An acneiform eruption due to erlotinib: prognostic implications and management

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039706

21 January 2018

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039706

21 January 2018

Strain-dependent epithelial defects in mice lacking the EGF receptor

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039706

21 January 2018

IL-8 as Antibody Therapeutic Target in Inflammatory Diseases: Reduction of Clinical Activity in Palmoplantar Pustulosis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039706

21 January 2018

The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

27 November 2018

Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382563

27 November 2018

Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular localisation of human epidermal growth factor receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Normal human epidermal keratinocyte-derived neutrophil chemotactic factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ERK1/2 regulates epidermal chemokine expression and skin inflammation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0039706

0 references

2012PLoSO...739706B

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28728031&oldid=1867118797"